Geodon for the Treatment of Refractory Social Anxiety Disorder

Phase 2 Completed 51 enrolled Duke University Pfizer · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone

Timeline

Start: 2004-11
Primary completion: 2008-12
Completion: 2009-07

Outcome

Missed primary endpoint

registry Randomization Phase for Ziprasidone Group vs Randomization Phase for Placebo Group; p > .05; Kruskal-Wallis NCT00215150 ↗

Publications

Background Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson W. The Brief Social Phobia Scale. J Clin Psychiatry. 1991 Nov;52 Suppl:48-51. doi: 10.1037/t07672-000.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sertraline	Small molecule	—	—
Subject	Ziprasidone	Small molecule	—	—